Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis
Conditions
Interventions
Double-Blind Adalimumab/Placebo + MTX
Double-Blind Adalimumab/Placebo
+2 more
Locations
31
United States
Site Ref # / Investigator 45524
Birmingham, Alabama, United States
Site Reference ID/Investigator# 2235
Los Angeles, California, United States
Site Reference ID/Investigator# 642
Stanford, California, United States
Site Reference ID/Investigator# 638
Delray Beach, Florida, United States
Site Ref # / Investigator 45543
St. Petersburg, Florida, United States
Site Reference ID/Investigator# 640
Chicago, Illinois, United States
Start Date
September 1, 2002
Primary Completion Date
January 1, 2005
Completion Date
June 1, 2010
Last Updated
August 22, 2011
NCT07349667
NCT06718569
NCT02593006
NCT00962741
Lead Sponsor
Abbott
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions